Silence Therapeutics plc filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-16. Each change below is quoted from the filing and linked to it.
Every change, newest first
Reported
As reported in the Original Form 8-K, effective as of December 14, 2025 (the "Separation Date"), Craig Tooman agreed by mutual consent to end his employment with Silence Therapeutics plc (the "Company").
Find people with the same kind of experience as the senior executive at Silence Therapeutics plc, with the record behind each one.
Find candidates like senior executive at Silence Therapeutics plcNew leaders review vendors and budgets in their first months. Get an alert the next time Silence Therapeutics plc is in the news or changes leadership.
Get an alert when Silence Therapeutics plc changes leadershipTools for this story
Each opens in a new tab, filled in for Silence Therapeutics plc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.